Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes Post-AlloSCT in DHL/DEL Lymphomas

Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Publish date:: December 13, 2017

Allogeneic stem cell transplantation (alloSCT) should be considered in patients with double-expressor lymphomas (DEL) and double-hit lymphomas (DHL), researchers concluded after conducting a retrospective analysis involving 78 individuals. Participants underwent alloSCT for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Investigators looked at the impact of DEL/DHL status. Among the results:

47% had DEL and 13% DHL.
4-year progression-free and overall survival rates were similar in patients with and without either DEL or DHL.
The findings held up after multivariate analysis, though researchers acknowledged the sample size might have prevented detecting significant differences.

Citation:

Herrera A, Rodig S, Song J, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. [Published online ahead of print November 28, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.11.023.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9